Clinical trial XL184-311
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
Cancers | |
---|---|
Organ | Thyroïd |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Exelixis |
EudraCT Identifier | 2018-001771-21 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03690388 |
Inclusion criteria | RECIST 1.1 |
Last update |